biostudies-literatureUnknown12Nguyen HT<h4>Background</h4>Colorectal cancer (CRC) is the fifth most common cancer with rising prevalence in Vietnam. However, there is no data about the mutational landscape and actionable alterations in the Vietnamese patients. During post-operative surveillance, clinical tools are limited to stratify risk of recurrence and detect residual disease.<h4>Method</h4>In this prospective multi-center study, 103 CRC patients eligible for curative-intent surgery were recruited. Genomic DNA from tumor tissue and paired white blood cells were sequenced to profile all tumor-derived somatic mutations in 95 cancer-associated genes. Our bioinformatic algorithm identified top mutations unique for individual patient, which were then used to monitor the presence of circulating tumor DNA (ctDNA) in serial plasma Frontiers in oncology1069296https://www.ebi.ac.uk/biostudies/studies/S-EPMC9792166biostudies-literatureTumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients.PMC9792166Dinh TCTruong DKNguyen XCNguyen Tran TANguyen TSGiang HLe MTPham DHNguyen TVLe Trinh NALu YTDo Thi TTNguyen Hoang VANguyen DSPham THTran DHNguyen The KCNguyen HNNguyen HTNguyen DQNgo Ha TMChu MTTu LNNguyen QTMai HfalseTumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients.<h4>Background</h4>Colorectal cancer (CRC) is the fifth most common cancer with rising prevalence in Vietnam. However, there is no data about the mutational landscape and actionable alterations in the Vietnamese patients. During post-operative surveillance, clinical tools are limited to stratify risk of recurrence and detect residual disease.<h4>Method</h4>In this prospective multi-center study, 103 CRC patients eligible for curative-intent surgery were recruited. Genomic DNA from tumor tissue and paired white blood cells were sequenced to profile all tumor-derived somatic mutations in 95 cancer-associated genes. Our bioinformatic algorithm identified top mutations unique for individual patient, which were then used to monitor the presence of circulating tumor DNA (ctDNA) in serial plasma 2022-01-01T00:00:00Z20222026-06-01T02:21:24.498Z2025-04-05T20:52:00.575ZS-EPMC97921663657894610.3389/fonc.2022.1069296